Sanofi

Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.

The French drug giant and its British counterpart GlaxoSmithKline surprised investors and customers last year when they announced a one-year delay to the launch of their joint COVID vaccine, based on a more conventional technology.

French pharmaceutical giant Sanofi and Britain's GSK announced Thursday the start of final tests of their belated Covid vaccine as they race to add their jab to the world's arsenal against the pandemic.

French pharmaceuticals giant Sanofi and Britain's GSK reported Monday positive results in clinical trials of their Covid-19 jab following an earlier setback, raising hope it could be added to the world's vaccine arsenal.

France's Sanofi and Britain's GSK said Friday their Covid-19 vaccines will not be ready until the end of 2021, after interim results showed a low immune response in older adults.

French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.

Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.

French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.

Sanofi chief executive Paul Hudson said on Thursday it was vital that any coronavirus vaccine reach all parts of the world, after angering the French government earlier by saying some countries would get priority access.

The French government cried foul Thursday after pharmaceutical giant Sanofi said it would reserve first shipments of any COVID-19 vaccine for the United States, saying the move would be "unacceptable" in a crisis that has killed nearly 300,000 people worldwide.

Pulled off air over a racist tweet, US sitcom star Roseanne Barr has blamed her outburst on a sleeping pill -- prompting a swift retort Wednesday from pharma giant Sanofi which stated, deadpan, that its drugs do not cause racism.

The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization programme after the French drugmaker said it could actually worsen the disease in some cases.

The company had posted a net profit of Rs 72.5 crore in the same quarter last fiscal, Sanofi India said in a BSE filing.

Sanofi-Pasteur - a unit of French pharmaceutical company Sanofi - that manufactures the only approved vaccine for dengue said today that the vaccines have received approval in 11 countries.

Biologics, manufactured in living cells, then extracted and purified, are more complex than traditional medicines and cannot be copied with precision, and so their knock-off versions are called biosimilars instead of generics.

Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.

The French drug giant and its British counterpart GlaxoSmithKline surprised investors and customers last year when they announced a one-year delay to the launch of their joint COVID vaccine, based on a more conventional technology.

French pharmaceutical giant Sanofi and Britain's GSK announced Thursday the start of final tests of their belated Covid vaccine as they race to add their jab to the world's arsenal against the pandemic.

French pharmaceuticals giant Sanofi and Britain's GSK reported Monday positive results in clinical trials of their Covid-19 jab following an earlier setback, raising hope it could be added to the world's vaccine arsenal.

France's Sanofi and Britain's GSK said Friday their Covid-19 vaccines will not be ready until the end of 2021, after interim results showed a low immune response in older adults.

French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the coronavirus pandemic.

Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.

French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.

Sanofi chief executive Paul Hudson said on Thursday it was vital that any coronavirus vaccine reach all parts of the world, after angering the French government earlier by saying some countries would get priority access.

The French government cried foul Thursday after pharmaceutical giant Sanofi said it would reserve first shipments of any COVID-19 vaccine for the United States, saying the move would be "unacceptable" in a crisis that has killed nearly 300,000 people worldwide.

Pulled off air over a racist tweet, US sitcom star Roseanne Barr has blamed her outburst on a sleeping pill -- prompting a swift retort Wednesday from pharma giant Sanofi which stated, deadpan, that its drugs do not cause racism.

The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization programme after the French drugmaker said it could actually worsen the disease in some cases.

The company had posted a net profit of Rs 72.5 crore in the same quarter last fiscal, Sanofi India said in a BSE filing.

Sanofi-Pasteur - a unit of French pharmaceutical company Sanofi - that manufactures the only approved vaccine for dengue said today that the vaccines have received approval in 11 countries.

Biologics, manufactured in living cells, then extracted and purified, are more complex than traditional medicines and cannot be copied with precision, and so their knock-off versions are called biosimilars instead of generics.